EU fines generic-drug companies to end "pay for delay" deals

06/3/2013 | Chicago Tribune (tiered subscription model)

The European Commission has announced fines against Lundbeck in Denmark, Merck in Germany and seven smaller firms for arrangements under which brand-name drug companies paid generic manufacturers to delay production of cheaper off-patent medicines. The fines mark a continuing effort by EU and US regulators to end such "pay for delay" tactics by large pharmaceutical firms. Lundbeck denied wrongdoing.

View Full Article in:

Chicago Tribune (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health